SCHEMBL1852593

SCHEMBL1852593

CC(C)C(Br)C(=O)Nc1c(C(N)=O)oc2ccc(Br)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.53
MAPT P10636 5/20 0.53
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 4/20 0.48
HPGD P15428 3/20 0.48
TSHR P16473 4/20 0.47
MEN1 O00255 4/20 0.47
HSD17B10 Q99714 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TP53 P04637 1/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
TEAD1 P28347 1/20 0.40
YAP1 P46937 1/20 0.40
TEAD4 Q15561 1/20 0.40
TEAD2 Q15562 1/20 0.40
ADORA2A P29274 1/20 0.40
CASP1 P29466 1/20 0.40
ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13787069 0.91 ALDH1A1 (0.46) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL1857370 0.90 KMT2A (0.54) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL1849131 0.87 KDM4E (0.54) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL13742016 0.84 ALDH1A1 (0.59) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL1851522 0.82 MAPT (0.57) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL1852360 0.82 KMT2A (0.47) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL13650759 0.79 ALDH1A1 (0.51) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL1851917 0.78 ALDH1A1 (0.48) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL1858218 0.77 TEAD1 (0.68) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL1853039 0.76 KMT2A (0.44) KMT2AMAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 KMT2A 2152/4885MAPT 1941/4885KDM4E 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.